Skip to main content

Table 2 Reasons not to participate in the consecutive recruitment phases

From: Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment

Letter returned (n = 1483)   
Reasons not to participate Total
(n)
Percentage
Few or no complaints 710 48.4%
Other allergy 240 16.4%
Study too burdensome 202 13.8%
No interest in the study 186 12.6%
No reason 145 9.8%
Telephone screening (n = 572)   
No HDM allergy 159 27.8%
Low symptom score (<4/12) 158 27.6%
Not interested in study 57 10.0%
Severe asthma 39 6.8%
Language barrier 27 4.7%
Use of immunotherapy in the last 3 years 19 3.3%
Refusing blood sample to be taken 17 3.0%
Age (out of range) 15 2.6%
Allergic complaints <1 year 12 2.1%
History of severe allergic reaction 9 1.6%
Systemic disease 8 1.4%
Use of nasal corticosteroids 1 month before baseline 7 1.2%
Answer forms received after deadline of inclusion period 45 7.9%
Screening visit (n = 249)   
Only grass pollen or tree pollen sensitization 81 32.5%
No sensitization detectable 75 30.1%
Sensitive to pet at home (confirmed by RAST) 60 24.1%
No informed consent 29 11.7%
Use of unallowed co-medication 4 1.6%